Run-in phase of prospective WSG ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by Recurrence Score and conventional parameters in clinical routine.: ID 455
In: Oncology Research and Treatment, Jg. 37 Supp 1 (2014-02-01), S. 9-10
Online
academicJournal
Titel: |
Run-in phase of prospective WSG ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by Recurrence Score and conventional parameters in clinical routine.: ID 455
|
---|---|
Autor/in / Beteiligte Person: | Harbeck, N. ; Gluz, O. ; Hofmann, D. ; Kreipe, H. H. ; Christgen, M. ; Svedman, C. ; Shak, S. ; Kümmel, S. ; Nuding, B. ; Rezai, N. ; Forstbauer, H. ; Würstlein, R. ; Kates, R. E. ; Nitz, U. |
Link: | |
Zeitschrift: | Oncology Research and Treatment, Jg. 37 Supp 1 (2014-02-01), S. 9-10 |
Veröffentlichung: | 2014 |
Medientyp: | academicJournal |
ISSN: | 2296-5270 (print) |
Sonstiges: |
|